16 reports

HALMRE-## - DRUG PROFILE POLLINEX QUATTRO GRASS - DRUG PROFILE Drug Name Company/ Institute Name Licensed From Company Development Partner Product Description Pollinex Quattro Grass Allergy Therapeutics Plc NA GlaxoSmithKline Plc R& D Progress Resea

  • Allergy Drug
  • Ophthalmic Solution
  • Pharmaceutical
  • Respiratory Disease
  • Product Initiative

The drug candidates target the allergens (Derp ##) that can trigger allergies and asthma attacks directly.

  • Asthma
  • Pharmaceutical
  • Research And Development
  • Respiratory Disease
  • AstraZeneca PLC

THE DRUG CANDIDATE ACTS BY TARGETING DIPEPTIDASE-##.

  • Blood Disease
  • Research And Development
  • Respiratory Disease
  • Therapy
  • Bristol-Myers Squibb Company

THE DRUG CANDIDATE IS A ## MER PEPTIDE ACTS BY TARGETING PROGRAMMED CELL DEATH ## LIGAND ## (PD-L##).

  • Blood Disease
  • Cell Therapy
  • Respiratory Disease
  • Therapy
  • Bristol-Myers Squibb Company

Patients were randomized in a ##:## fashion to active drug versus placebo.

  • Monoclonal Antibody
  • Respiratory Disease
  • Therapy
  • United States
  • Product Initiative

The drug candidate activates allergen-specific T-helper type ## (Th##) cellular responses with the production of interferons by antigen presenting cells (APC), natural killer cells (NK), and T cells.

  • Allergy Drug
  • Ophthalmic Solution
  • Pharmaceutical
  • Respiratory Disease
  • Allergy Therapeutics plc

The drug candidate is in Phase II stage for peanut allergy in adults and pediatrics, grass pollen allergy and dermatitis globally.

  • Digestive System Disorder
  • Respiratory Disease
  • Therapy
  • United States
  • Product Initiative

The drug candidate is in Phase II stage for peanut allergy, grass pollen allergy, chronic urticaria, and dermatitis globally.

  • Chronic Disease
  • Respiratory Disease
  • United States
  • Product Initiative
  • Regeneron Pharmaceuticals, Inc.

ABOUT ## PERCENT OF PEOPLE WHO HAVE FOOD ALLERGIES ARE ALLERGIC TO MORE THAN ONE FOOD.

  • Pharmaceutical
  • Respiratory Disease
  • Therapy
  • United States
  • Product Initiative

One group was given ##mg of the drug twice a day for ## weeks and the other participants were assigned to a placebo group.

  • Asthma
  • Respiratory Disease
  • United States
  • World
  • Product Initiative

In July 2011, Oxagen Limited announced publication of data from a Phase IIa clinical trial of its development drug OC## in the journal Clinical & Experimental Allergy.

  • Pharmaceutical
  • Respiratory Disease
  • United States
  • World
  • Product Initiative

About ## percent of people who have food allergies are allergic to more than one food.

  • Chronic Disease
  • Respiratory Disease
  • United States
  • Product Initiative
  • Regeneron Pharmaceuticals, Inc.

About ## percent of people who have food allergies are allergic to more than one food.

  • Monoclonal Antibody
  • Pharmaceutical
  • Respiratory Disease
  • Therapy
  • Regeneron Pharmaceuticals, Inc.

One group was given ##mg of the drug twice a day for ## weeks and the other participants were assigned to a placebo group.

  • Asthma
  • Respiratory Disease
  • Therapy
  • World
  • Product Initiative

THE DRUG CANDIDATE IS A MUTANT DERIVATIVE BIRCH POLLEN ALLERGEN BET V ##.

  • Allergy Drug
  • Allergy Immunotherapy
  • Respiratory Disease
  • Therapy
  • Product Initiative

The company offers drugs in the areas of nephrology, oncology, immunology and allergy, central nervous system among others.

  • Immunotherapy
  • Research And Development
  • Respiratory Disease
  • Therapy
  • AstraZeneca PLC